ANGO vs. ARAY, SRDX, CTSO, OFIX, UTMD, RCEL, TLSI, SGHT, PROF, and DRTS
Should you be buying AngioDynamics stock or one of its competitors? The main competitors of AngioDynamics include Accuray (ARAY), Surmodics (SRDX), Cytosorbents (CTSO), Orthofix Medical (OFIX), Utah Medical Products (UTMD), AVITA Medical (RCEL), TriSalus Life Sciences (TLSI), Sight Sciences (SGHT), Profound Medical (PROF), and Alpha Tau Medical (DRTS). These companies are all part of the "surgical & medical instruments" industry.
AngioDynamics (NASDAQ:ANGO) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking.
AngioDynamics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.
In the previous week, Accuray had 18 more articles in the media than AngioDynamics. MarketBeat recorded 21 mentions for Accuray and 3 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 0.47 beat Accuray's score of -0.26 indicating that AngioDynamics is being referred to more favorably in the media.
Accuray has higher revenue and earnings than AngioDynamics. Accuray is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
Accuray has a net margin of -4.99% compared to AngioDynamics' net margin of -60.21%. AngioDynamics' return on equity of -3.48% beat Accuray's return on equity.
AngioDynamics presently has a consensus price target of $14.25, suggesting a potential upside of 127.27%. Accuray has a consensus price target of $8.25, suggesting a potential upside of 409.26%. Given Accuray's higher possible upside, analysts clearly believe Accuray is more favorable than AngioDynamics.
89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 5.1% of AngioDynamics shares are held by company insiders. Comparatively, 3.8% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
AngioDynamics received 30 more outperform votes than Accuray when rated by MarketBeat users. However, 65.67% of users gave Accuray an outperform vote while only 60.67% of users gave AngioDynamics an outperform vote.
Summary
AngioDynamics beats Accuray on 9 of the 17 factors compared between the two stocks.
Get AngioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AngioDynamics Competitors List
Related Companies and Tools
